OnKure Therapeutics Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 8
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $55M
Latest Deal Amount
  • Investors
  • 8

OnKure Therapeutics General Information

Description

Developer of class precision medicines intended to offer epigenetic therapies for the treatment of cancer. The company's medicine engages in the discovery and development of therapies reducing the growth rate of tumors when dosed by itself or in combination with other targeted therapies, thereby enabling cancer patients to get access to treatments that include selective inhibitors of histone deacetylases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 1105 Spruce Street
  • Boulder, CO 80302
  • United States
+1 (720) 000-0000

OnKure Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

OnKure Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series B) 03-Mar-2021 $55M 000.00 00000 Completed Clinical Trials - Phase 2
5. Later Stage VC 30-Sep-2020 00.00 000.00 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series A1) 15-Apr-2020 00.000 000.00 000.00 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series A) 02-May-2018 000 00.00 0000 Completed Clinical Trials - Phase 2
2. Angel (individual) 04-Jun-2013 $600K $1.1M Completed Startup
1. Angel (individual) 09-Apr-2013 $500K $500K Completed Startup
To view OnKure Therapeutics’s complete valuation and funding history, request access »

OnKure Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A-1 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A 2,758,788 $0.000100 $1.89 $1.89 1x $1.89 7.26%
To view OnKure Therapeutics’s complete cap table history, request access »

OnKure Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of class precision medicines intended to offer epigenetic therapies for the treatment of cancer. The company's
Drug Discovery
Boulder, CO
8 As of 2019
000.00
0000 0000-00-00
00000000000 000.00

000000 0

ercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehe
0000 000000000
San Diego, CA
000 As of 0000
00000
00000000 00000

000000

, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
0000 000000000
Waltham, MA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OnKure Therapeutics Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mirati Therapeutics Formerly PE-Backed San Diego, CA 000 00000 00000000 00000
000000 Formerly VC-backed Waltham, MA 00 00000 000000000 00000
You’re viewing 2 of 2 competitors. Get the full list »

OnKure Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Anthony Piscopio Ph.D Co-Founder, President, Chief Executive Officer & Board Member
John DeMattei Chief Operating Officer & Vice President of Chemistry
Jim Winkler Ph.D Chief Scientific Officer
Gail Eckhardt MD Chief Medical Officer
Michael Carruthers Chief Financial Officer
To view OnKure Therapeutics’s complete executive team members history, request access »

OnKure Therapeutics Board Members (8)

Name Representing Role Since
Andrew Phillips Ph.D Cormorant Asset Management Board Member 000 0000
Anthony Piscopio Ph.D OnKure Therapeutics Co-Founder, President, Chief Executive Officer & Board Member 000 0000
Donna Peak OnKure Therapeutics Board Member 000 0000
Guobao Zhao Delian Capital Board Member 000 0000
Isaac Manke Ph.D Acorn Bioventures Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

OnKure Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OnKure Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Acorn Bioventures Corporation Minority 000 0000 000000 0
BlackRock Asset Manager Minority 000 0000 000000 0
Citadel (Hedge Fund) Hedge Fund Minority 000 0000 000000 0
Cormorant Asset Management Hedge Fund Minority 000 0000 000000 0
Perceptive Advisors Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »